[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Instituto do Coracao\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100644144","phase-3-continuous-esp-block-in-patients-undergoing-cabg-surgery-100644144",false,"NCT07666178","Continuous ESP Block in Patients Undergoing CABG Surgery.","Continuous Erector Spinea Plane Block in Patients Undergoing Coronary Artery By-pass Graft Surgery.","Inclusion Criteria:\n\n* Consent to the free and informed consent term.\n* Patient undergoing coronary artery bypass graft surgery with cardiopulmonary bypass (CPB).\n* Preserved left ventricular global function (LVEF \\> 50%).\n\nExclusion Criteria:\n\n* Moderate or severe valvular dysfunction.\n* Previous anterior sternotomy.\n* Known allergy to the study drugs.\n* Complications during catheter insertion or block placement.\n* Pre-existing diagnosed chronic pain under treatment.\n* Concomitant use of drugs with a long half-life (induction and anesthetic maintenance doses will be standardized; patients taking medications with a long half-life are excluded to prevent bias in outcome assessment).\n* Concomitant administration of Magnesium Sulfate.","ALL",{"count":18,"type":19},78,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","This study addresses articles and studies related to the erector spinae plane (ESP) block and its technique, advantages and disadvantages, applicability, among others. It aims to provide more information about this block, which is relatively new, and how it can be explored in the anesthesiologist's routine, mainly inserted in the anesthesia scenario for cardiac surgery with a focus on postoperative analgesia.",[25],"Erector Spinae Plane Block",[27,28,29,30,31],"Spinae erector block","esp block","Analgesia","Continuous analgesia","block","RECRUITING","2026-06-18",{"date":35,"type":36},"2026-06-24","ACTUAL",{"date":38,"type":36},"2024-12-12",{"date":40,"type":19},"2027-12-12",{"name":42,"class":43},"Instituto do Coracao","OTHER_GOV",1,{"id":46,"slug":4,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":44},"100607991","NCT07195747","Effects of Surgical, Percutaneous or Medical Treatments for Coronary Artery Disease on Renal Function: Long-Term Outcome. Cardiorenal-trial.","Inclusion Criteria:\n\n* Multivessel coronary artery disease (CAD) documented by angiography (2 or more epicardial arteries with stenosis of 70% or more);\n* Preserved left ventricular systolic function;\n* Have undergone treatment with medical therapy (MT), coronary artery bypass graft (CABG) or percutaneous coronary artery intervention (PCI), using drug-eluting stents (DES) or bare-metal stents (BMS);\n* Availability of baseline serum creatinine values at the time of enrollment;\n* Availability of serum creatinine measurements for a minimum of five years.\n\nExclusion Criteria:\n\n* Presence of acute coronary syndrome at baseline;\n* Limited life expectancy due to noncardiac comorbidities;\n* Inability to maintain regular outpatient follow-up;\n* Significant left main coronary artery disease (stenosis greater than 50%);\n* Advanced chronic kidney disease (estimated glomerular filtration rate \\[eGFR\\] less than 30mL\u002Fmin\u002F1,73m2);\n* End-stage renal disease requiring dialysis or history of kidney transplantation.",{"count":51,"type":19},1700,"OBSERVATIONAL","Background: Coronary artery disease (CAD) is treated with coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), or optimized medical therapy (OMT). Their cardiovascular outcomes are well studied, but renal effects remain unclear.\n\nObjective: To evaluate long-term renal outcomes of different CAD treatment strategies.\n\nMethods: In this retrospective cohort from the MASS registry, patients with stable multivessel CAD and preserved ventricular function underwent OMT, CABG, or PCI. Annual creatinine was measured for ≥5 years, and eGFR calculated using CKD-EPI. The primary endpoint was change in renal function over time. Secondary endpoints included new-onset CKD, progression to advanced CKD, dialysis, and mortality. Analyses will use mixed-effects models and Cox regression.\n\nResults: Over 1,700 patients met inclusion criteria. Longitudinal follow-up enables robust comparison of renal trajectories across treatment groups.\n\nConclusions: This trial highlights renal function as a primary outcome in CAD management, aiming to inform integrated strategies for patients with concurrent cardiovascular and renal risk.",[55,56],"Coronary Artery Disease","Chronic Kidney Disease",[55,56,58,59,60,61,62],"Renal Function","Coronary Artery Bypass Grafting (CABG)","Percutaneous Coronary Intervention (PCI)","Medical Therapy","Log-Term Outcomes","NOT_YET_RECRUITING","2025-09-19",{"date":66,"type":36},"2025-09-29",{"date":68,"type":19},"2025-10-01",{"date":70,"type":19},"2028-12",{"name":42,"class":43},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":20,"phases":82,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":44},"100321789","goal-directed-therapy-aiming-to-optimise-oxygen-central-venous-saturation-in-children-undergoing-cardiac-surgery-100321789","NCT03469440","Goal Directed Therapy Aiming to Optimise Oxygen Central Venous Saturation in Children Undergoing Cardiac Surgery","Goal Directed Therapy Aiming to Optimise Oxygen Central Venous Saturation in Children Undergoing Cardiac Surgery: a Randomized and Prospective Clinical Trial","Inclusion Criteria:\n\n* Elective cardiac surgery with cardiopulmonary bypass\n* Written informed consent\n\nExclusion Criteria:\n\n* Cardiac arrhythmia\n* Emergency operation\n* Hemodynamic instabillty (norepinephrine higher than 1 mcg\u002Fkg\u002Fmin)\n* Neoplasia\n* Heart transplant\n* Participation in another study","14 Years",{"count":81,"type":19},65,[83],"NA","The purpose of this study is evaluate goal-directed therapy with continuous central venous saturation compared to standard therapy in children undergoing cardiac surgery.",[86,87],"Heart; Dysfunction Postoperative, Cardiac Surgery","C.Surgical Procedure; Cardiac",[89,90,91],"lactate","central venous saturation","Pediatric Cardiac Surgery","2024-08-21",{"date":94,"type":36},"2024-08-23",{"date":96,"type":36},"2018-02-01",{"date":98,"type":19},"2024-12",{"name":42,"class":43},""]